Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

A. Saroufim, Y. Messai, M. Hasmim, N. Rioux, R. Iacovelli, G. Verhoest, K. Bensalah, J. J. Patard, L. Albiges, B. Azzarone, B. Escudier, S. Chouaib

Research output: Contribution to journalArticle

Abstract

Background:Angiogenesis is essential for tumour growth and metastasis. There are conflicting reports as to whether microvessel density (MVD) using the endothelial marker CD105 (cluster of differentiation molecule 105) in clear-cell renal cell carcinomas (ccRCC) is associated with prognosis. Recently, CD105 has been described as a RCC cancer stem cell marker.Methods:A total of 102 ccRCC were analysed. Representative tumour sections were stained for CD105. Vascularity (endothelial CD105) was quantified by MVD. The immunohistochemistry analysis detected positive (if present) or negative (if absent) CD105 tumoral staining. This retrospective population-based study was evaluated using Kaplan-Meier method, t-test and Cox proportional hazard model.Results:We found that the expression of endothelial CD105 (MVD) negatively correlated with nuclear grade (P

Original languageEnglish
Pages (from-to)1778-1784
Number of pages7
JournalBritish Journal of Cancer
Volume110
Issue number7
DOIs
Publication statusPublished - Apr 1 2014

Keywords

  • ccRCC
  • CD105
  • endothelial
  • prognosis
  • tumoral

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Saroufim, A., Messai, Y., Hasmim, M., Rioux, N., Iacovelli, R., Verhoest, G., Bensalah, K., Patard, J. J., Albiges, L., Azzarone, B., Escudier, B., & Chouaib, S. (2014). Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. British Journal of Cancer, 110(7), 1778-1784. https://doi.org/10.1038/bjc.2014.71